2. Lipids
  3. Isotope-Labeled Lipids
  4. Isotope-Labeled Fatty Esters
  5. Isotope-Labeled Fatty Acid Estolides

Isotope-Labeled Fatty Acid Estolides

Isotope-Labeled Fatty Acid Estolides (8):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W770410
    9-PAHSA-13C4 2748638-71-1 99.9%
    9-PAHSA-13C4 is 13C-labeled 9-PAHSA. 9-PAHSAis an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSAsignificantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSAinduces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSAregulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSAdoes not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSAcan be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease.
    9-PAHSA-<sup>13</sup>C<sub>4</sub>
  • HY-144026S
    9-PAHSA-d9 1809222-43-2
    9-PAHSA-d9 is the deuterium labeled 9-PAHSA (HY-120657). 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease.
    9-PAHSA-d<sub>9</sub>
  • HY-133851S1
    10-PAHSA-13C4 2705244-93-3
    10-PAHSA-13C4 is the 13C-labeled 10-PAHSA. 10-PAHSA is an endogenous lipid that belongs to a collection of branched fatty acid esters of hydroxy fatty acids (FAHFAs).
    10-PAHSA-<sup>13</sup>C<sub>4</sub>
  • HY-144024S
    5-PAHSA-d9 1809226-17-2
    5-PAHSA-d9 is the deuterium labeled 5-PAHSA (HY-116193). 5-PAHSA is a kind of anti-inflammatory and antidiabetic lipokines that connect glucose and lipid metabolism.
    5-PAHSA-d<sub>9</sub>
  • HY-113878S
    12-OAHSA-d17
    12-OAHSA-d17 is the deuterium labeled 12-OAHSA.
    12-OAHSA-d<sub>17</sub>
  • HY-120657S
    9-PAHSA-d4 2704278-85-1
    9-PAHSA-d4 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease.
    9-PAHSA-d<sub>4</sub>
  • HY-116193S
    5-PAHSA-d31 2749807-01-8
    5-PAHSA-d31 is the deuterium labeled 5-PAHSA.
    5-PAHSA-d<sub>31</sub>
  • HY-120657S1
    9-PAHSA-d31 2748208-06-0 99.00%
    9-PAHSA-d31 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease.
    9-PAHSA-d<sub>31</sub>